No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PTCT240517C29000
- 3.50
- +2.25+180.00%
15min DelayClose May 10 15:59 ET
3.50High3.30Low
3.30Open1.25Pre Close2 Volume10 Open Interest29.00Strike Price680.00Turnover160.80%IV3.49%PremiumMay 17, 2024Expiry Date3.25Intrinsic Value100Multiplier5DDays to Expiry0.25Time Value100Contract SizeAmericanOptions Type0.7400Delta0.0512Gamma7.37Leverage Ratio-0.1982Theta0.0029Rho5.45Eff Leverage0.0128Vega
Intraday
- 5D
- 1D
News
HHS Panel to Vote in Nov. on DMD Screening for Newborns
Boy Given Pfizer Experimental Duchenne Muscular Dystrophy Therapy Dies
PTC Therapeutics to Participate at Upcoming Investor Conferences
WARREN, N.J., May 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: RBC Capital Markets 2024
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2024 Earnings Call Transcript
Express News | PTC Therapeutics Shares Are Trading Higher After Morgan Stanley Upgraded the Stock From Underweight to Equal-Weight and Raised Its Price Target From $28 to $30
Express News | PTC Therapeutics Inc : Morgan Stanley Raises Target Price to $30 From $28
Comments
PTC Therapeutics' low P/S ratio is seen as reasonable due to industry underperformance. However, weak revenue outlook is pressuring shares, making maintaining current prices challenging. Shareholders accept the low P/S, expecting no future revenue surprises.
There's No Escaping PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Muted Revenues Despite A 27% Share Price RiseRecent insider selling at PTC Therapeutics outweighs insider buying, a potential bearish sign. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership suggests alignment with shareholders, but insider selling warrants caution.
1
PTC Therapeutics' ongoing losses may have led to negative market view, causing a contradictory movement in the stock against the company’s revenue growth. The firm's underperformance in the past five years suggests unresolved issues. Currently, the healthcare company has five investment analysis warning signs.
$PTC Therapeutics(PTCT.US$ 🚀🚀🚀🚀🚀🚀🚀🔥🔥🔥🔥🔥🔥🔥 Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- R...
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- R...
Read more